SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-15-050315
Filing Date
2015-02-13
Accepted
2015-02-13 17:05:00
Documents
4
Group Members
JOSHUA WOLFELUX CAPITAL MANAGEMENT, LLCLUX VENTURE ASSOCIATES II, LLCLUX VENTURE PARTNERS II, L.P.LUX VENTURES II PARTNERS FUND I LLCLUX VENTURES II SIDECAR, L.P.PETER HEBERT

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G d874036dsc13ga.htm SC 13G/A 135214
2 EX-99.1 d874036dex991.htm EX-99.1 19117
3 EX-99.2 d874036dex992.htm EX-99.2 947
4 EX-99.3 d874036dex993.htm EX-99.3 18318
  Complete submission text file 0001193125-15-050315.txt   175423
Mailing Address 840 MEMORIAL DRIVE 5TH FLOOR Cambridge MA 02139
Business Address 840 MEMORIAL DRIVE 5TH FLOOR Cambridge MA 02139 617-551-9600
Cerulean Pharma Inc. (Subject) CIK: 0001401914 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88094 | Film No.: 15616053
SIC: 2834 Pharmaceutical Preparations

Mailing Address 295 MADISON AVENUE, 24TH FLOOR NEW YORK NY 10017
Business Address 295 MADISON AVENUE, 24TH FLOOR NEW YORK NY 10017 646-475-4385
Lux Ventures II, L.P. (Filed by) CIK: 0001592755 (see all company filings)

IRS No.: 000000000
Type: SC 13G/A